August 21, 2018
Fitch Even partner Kendrew H. Colton is quoted in an article published in the August 19, 2018 issue of Chemical & Engineering News, a weekly publication of the American Chemical Society.
The article, titled "Firms Feud Over Niagen, A Purported Age-Fighting Molecule," discusses the ongoing patent dispute between ChromaDex and Elysium Health over rights to nicotinamide riboside or NR, a molecule with promising vitamin-like qualities.
Ken has been practicing intellectual property law for over 30 years. His primary practice focus is counseling clients on a wide range of IP matters involving established and emerging chemical and biochemical technologies. Ken has been a member of the Chemical & Engineering News Advisory Board since 2012.
- Leveraging Separate IPR Counsel to Maximize Litigation SuccessFitch Even Webinar: November 18, 2021 Read more
IP Alert | USPTO Abused Discretion by Allowing Further Abuse by Ex Parte ReexaminationOctober 22, 2021
On September 29, in In re Vivint, Inc., the Federal Circuit clarified the interplay between petitions for IPR and a subsequent request for ex parte reexamination. Read more